SCHEMBL6091049

SCHEMBL6091049

COc1ccc(C(=O)Nc2ccc(O)cc2C(=O)O)cc1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.74
ABL1 P00519 2/20 0.74
RIN1 Q13671 2/20 0.74
MAPT P10636 4/20 0.70
KMT2A Q03164 5/20 0.64
MEN1 O00255 4/20 0.64
RAB9A P51151 2/20 0.64
LMNA P02545 1/20 0.64
ALDH1A1 P00352 5/20 0.63
HTT P42858 2/20 0.63
AKR1C4 P17516 1/20 0.62
AKR1C3 P42330 1/20 0.62
AKR1C2 P52895 1/20 0.62
AKR1C1 Q04828 1/20 0.62
CHEK1 O14757 1/20 0.61
PIM1 P11309 1/20 0.61
MAPK8 P45983 1/20 0.61
CLK4 Q9HAZ1 1/20 0.61
PDE4D Q08499 1/20 0.57
NPC1 O15118 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095280 0.91 CHEK1 (0.63) TDP1ABL1RIN1MAPTKMT2A
SCHEMBL6093998 0.90 TDP1 (0.74) TDP1ABL1RIN1MAPTKMT2A
SCHEMBL4670317 0.87 CHEK1 (0.81) TDP1ABL1RIN1KMT2AMEN1
SCHEMBL9973844 0.83 MEN1 (0.69) TDP1ABL1RIN1MAPTKMT2A
SCHEMBL14227329 0.82 MEN1 (0.82) TDP1ABL1RIN1MAPTKMT2A
SCHEMBL14290075 0.82 PDE4D (0.55) TDP1ABL1RIN1MAPTKMT2A
SCHEMBL823124 0.81 MEN1 (0.84) TDP1ABL1RIN1MAPTKMT2A
SCHEMBL6092606 0.81 CHEK1 (0.63) TDP1ABL1RIN1MAPTKMT2A
SCHEMBL2810656 0.80 MEN1 (0.82) TDP1ABL1RIN1MAPTKMT2A
SCHEMBL29367215 0.80 MEN1 (0.82) TDP1ABL1RIN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE SYMRISE AG (DE) 2023-04-27 US disclosed
US-20230118467-A1 COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L SYMRISE AG (DE) 2023-04-20 US disclosed
EP-1959915-B1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE AG (DE) 2015-05-13 EP disclosed
US-8911795-B2 Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching SYMRISE AG (DE) 2014-12-16 US disclosed
US-8911795-B2 Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching SYMRISE AG (DE) 2014-12-16 US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 US disclosed
US-20120315233-A1 ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS SYMRISE AG (DE) 2012-12-13 US disclosed
US-8203016-B2 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE AG (DE) 2012-06-19 US disclosed
US-8203016-B2 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE AG (DE) 2012-06-19 US disclosed
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching SYMRISE GMBH & CO. KG (DE) 2009-12-03 US disclosed
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching SYMRISE GMBH & CO. KG (DE) 2009-12-03 US disclosed
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2009-09-10 US disclosed
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2009-09-10 US disclosed
US-20080008660-A1 Antimicrobially active compounds for treating bad breath SYMRISE GMBH & CO. KG (DE) 2008-01-10 US disclosed
US-20080008660-A1 Antimicrobially active compounds for treating bad breath SYMRISE GMBH & CO. KG (DE) 2008-01-10 US disclosed
WO-2007062957-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2007-06-07 WO disclosed
US-20060089413-A1 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE GMBH & CO. KG (DE) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089413-A1 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents HRH1, CMA1, HRH2 TDP1 3451/4885ABL1 1243/4885RIN1 1968/4885
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching H1-0, ASIC1, MCOLN1 TDP1 2244/4885ABL1 2007/4885RIN1 1637/4885
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE HPD, CYP4A22, PAH TDP1 1126/4885ABL1 2838/4885RIN1 4683/4885
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING H1-0, ASIC1, NHERF1 TDP1 2675/4885ABL1 1758/4885RIN1 1253/4885
US-20120315233-A1 ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS CMA1, TPSAB1, HRH1 TDP1 2841/4885ABL1 1442/4885RIN1 2246/4885
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY OAT, PIGS, HLA-A TDP1 2559/4885ABL1 3575/4885RIN1 4477/4885
US-20080008660-A1 Antimicrobially active compounds for treating bad breath CAT, LPO, GPX1 TDP1 2282/4885ABL1 2223/4885RIN1 1448/4885
US-20230118467-A1 COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L TACR1, NPSR1, TACR2 TDP1 1801/4885ABL1 4731/4885RIN1 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.